Immunotherapy of MHC class I-deficient tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F10%3A00352661" target="_blank" >RIV/68378050:_____/10:00352661 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Immunotherapy of MHC class I-deficient tumors
Original language description
MHC class I downregulation is a general mechanism by which tumor cells can escape from T-cell-mediated immunity. Therefore, successful imunotherapeutic and vaccination protocols should be optimized against tumors with distinct cell surface expression ofthe MHC class I molecules. Mechanisms leading to protective immunity may vary in different models with respect to the particular tumors, e.g. to their levels of residual expression of the MHC class I molecules on tumor cells or inducibility of MHC classI expression. Notably, both CD8+ cell-mediated immunity and MHC class I-unrestricted mechanisms can take place against MHC class I-deficient tumors. Since MHC class I downregulation is frequently reversible by cytokines and also by activation of epigenetically silenced genes, an attractive strategy is to elicit specific cell-mediated immunity combined with restoration of MHC class I expression on tumor cells.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)